Study of HER2, ER and PR markers and survival in invasive ductal carcinoma patients in south-east Romania

References

• Singhai R, Patil V, Patil A. Status of HER-2/neu receptors and Ki-67 in breast cancer of Indian women. Int J Appl Basic Med Res. 2011;1(1):15–19.
   Google Scholar
• Bozhok AA, Semiglazov VF, Semiglazov VV, et al. Prognostic and predictive factors in breast cancer. Vopr Onkol. 2005;51(4):434–443. Russian.
   PubMedGoogle Scholar
• Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997–4013.
   PubMed Web of Science ®Google Scholar
• Hammond MEH, Hayes DF, Dowsett M, et al. ASCO-CAP guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–2795.
   PubMed Web of Science ®Google Scholar
• Hammond MEH, Hayes DF, Dowsett M, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(7):e48–e72.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Rumble RB, Carey LA, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32(29):3307–3329.
   PubMed Web of Science ®Google Scholar
• Lumachi F, Brunello A, Maruzzo M, et al. Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013;20(5):596–604.
   PubMed Web of Science ®Google Scholar
• Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95:142–153.
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808–3816.
   PubMed Web of Science ®Google Scholar
• Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6,556 breast cancer tissues. Clin Breast Cancer. 2004;5:63–69.
   PubMedGoogle Scholar
• Autier P, Boniol M, LaVecchia C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010;341:c3620.
   PubMed Web of Science ®Google Scholar
• Vrdoljak E, Wojtukiewicz MZ, Pienkowski T, et al. Cancer epidemiology in Central and South Eastern European countries. Croat Med J. 2011;52(4):478–487.
   PubMed Web of Science ®Google Scholar
• Pukkala E, Kesminiene A, Poliakov S, et al. Breast cancer in Belarus and Ukraine after the Chernobyl accident. Int J Cancer. 2006;119(3):651–658.
   PubMed Web of Science ®Google Scholar
• Fota GL, Stepan A, Ciurea RN. The evaluation of the immunoexpression of Her2/neu oncoprotein in ductal carcinoma in situ in association with invasive ductal carcinoma of the breast. Rom J Morphol Embryol. 2012;53(3 Suppl):805–881.
   PubMed Web of Science ®Google Scholar
• Enache DE, Georgescu CV, Pătrană N. Negative estrogen-receptor invasive breast carcinoma: mammographic aspects, correlations with HER2/neu oncoprotein status. Rom J Morphol Embryol. 2012;53(3 Suppl):755–776.
   PubMed Web of Science ®Google Scholar
• Varma G, Varma R, Huang H, et al. Array comparative genomic hybridisation (aCGH) analysis of premenopausal breast cancers from a nuclear fallout area and matched cases from Western New York. Br J Cancer. 2005;93(6):699–708.
   PubMed Web of Science ®Google Scholar
• Kuzhan A, Adli M, Eryigit Alkis H, et al. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey. J BUON. 2013;18(3):619–622.
   PubMed Web of Science ®Google Scholar
• Amend K, Hicks D, Ambrosone C. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res. 2006;66:8327–8330.
   PubMed Web of Science ®Google Scholar
• Mustać E, Zamolo G, Petković M, et al. Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker. Coll Antropol. 2008;32(3):741–746.
   PubMed Web of Science ®Google Scholar
• Yao LH, Jiang YM, Shi J, et al. Flavonoids in food and their health benefits. Plant Foods Hum Nutr. 2004;59(3):113–122.
   PubMed Web of Science ®Google Scholar
• Holmes MD, Willett WC. Does diet affect breast cancer risk? Breast Cancer Res. 2004;6(4):170–178.
   PubMed Web of Science ®Google Scholar
• Hystad P, Villeneuve PJ, Goldberg MS, et al. Exposure to traffic-related air pollution and the risk of developing breast cancer among women in eight Canadian provinces: a case–control study. Environ Int. 2015;74:240–248.
   PubMed Web of Science ®Google Scholar
• Elias AD. Triple-negative breast cancer: a short review. Am J Clin Oncol. 2010;33(6):637–645.
   PubMed Web of Science ®Google Scholar
• Yıldız B, Fidan E, Ozdemir F, et al. Clinicopathological characteristics of triple-negative breast cancers in the northeast region of Turkey. Balkan Med J. 2014;31(2):126–131.
   Google Scholar
• Zhang Z, Wang J, Tacha DE, et al. Folate receptor α associated with triple-negative breast cancer and poor prognosis. Arch Pathol Lab Med. 2014; 138(7):890–895.
   PubMed Web of Science ®Google Scholar
• Rais G, Raissouni S, Aitelhaj M, et al. Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology. BMC Womens Health. 2012;12:35. Available from: http://www.biomedcentral.com/1472-6874/12/35.
   PubMedGoogle Scholar
• Wang SL, Li YX, Song YW, et al. Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy. Zhonghua Zhong Liu Za Zhi. 2010;32(7):520–525. Chinese.
   Google Scholar
• Fan Y, Guan Y, Zhao WH, et al. Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression. Zhonghua Zhong Liu Za Zhi. 2008;30(12):917–920. Chinese.
   PubMedGoogle Scholar
• van der Hage JA, Mieog JS, van de Vijver MJ, et al. Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis. Breast Cancer Res. 2007;9(5):R70.
   PubMed Web of Science ®Google Scholar